Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki; Rika Sakai; Noriko Iwaki; Go Yamamoto; Kayoko Murayama; Momoko Nishikori; Kazutaka Sunami; Isao Yoshida; Hiroki Yano; Naoki Takahashi; Akinao Okamoto; Saori Munemoto; Aiko Sawazaki; Youko Suehiro; Noriko Fukuhara; Atsushi Wake; Ayako Arai; Yasufumi Masaki; Kohtaro Toyama; Akihiro Yokoyama; Hiroko Tsunemine; Yuichi Hasegawa; Kenji Matsumoto; Tomomi Yamada; Yuki Nishimura; Satoshi Tamaru; Naoko Asano; Kohta Miyawaki; Koji Izutsu; Tomohiro Kinoshita; Ritsuro Suzuki; Koichi Ohshima; Koji Kato; Naoyuki Katayama; Motoko Yamaguchi

doi:10.1111/cas.15784

Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Kana Miyazaki, Rika Sakai, Noriko Iwaki, Go Yamamoto, Kayoko Murayama, Momoko Nishikori, Kazutaka Sunami, Isao Yoshida, Hiroki Yano, Naoki Takahashi, Akinao Okamoto, Saori Munemoto, Aiko Sawazaki, Youko Suehiro, Noriko Fukuhara, Atsushi Wake, Ayako Arai, Yasufumi Masaki, Kohtaro Toyama, Akihiro YokoyamaHiroko Tsunemine, Yuichi Hasegawa, Kenji Matsumoto, Tomomi Yamada, Yuki Nishimura, Satoshi Tamaru, Naoko Asano, Kohta Miyawaki, Koji Izutsu, Tomohiro Kinoshita, Ritsuro Suzuki, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi

研究成果: ジャーナルへの寄稿 › Letter › 査読

1 被引用数 (Scopus)

本文言語	英語
ページ（範囲）	2689-2691
ページ数	3
ジャーナル	Cancer science
巻	114
号	6
DOI	https://doi.org/10.1111/cas.15784
出版ステータス	出版済み - 06-2023
外部発表	はい

All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1111/cas.15784

他のファイルとリンク

引用スタイル

Miyazaki, K., Sakai, R., Iwaki, N., Yamamoto, G., Murayama, K., Nishikori, M., Sunami, K., Yoshida, I., Yano, H., Takahashi, N., Okamoto, A., Munemoto, S., Sawazaki, A., Suehiro, Y., Fukuhara, N., Wake, A., Arai, A., Masaki, Y., Toyama, K., ... Yamaguchi, M. (2023). Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer science, 114(6), 2689-2691. https://doi.org/10.1111/cas.15784

@article{7f75e161d990483b9d5f89937bf93c60,

title = "Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL",

author = "Kana Miyazaki and Rika Sakai and Noriko Iwaki and Go Yamamoto and Kayoko Murayama and Momoko Nishikori and Kazutaka Sunami and Isao Yoshida and Hiroki Yano and Naoki Takahashi and Akinao Okamoto and Saori Munemoto and Aiko Sawazaki and Youko Suehiro and Noriko Fukuhara and Atsushi Wake and Ayako Arai and Yasufumi Masaki and Kohtaro Toyama and Akihiro Yokoyama and Hiroko Tsunemine and Yuichi Hasegawa and Kenji Matsumoto and Tomomi Yamada and Yuki Nishimura and Satoshi Tamaru and Naoko Asano and Kohta Miyawaki and Koji Izutsu and Tomohiro Kinoshita and Ritsuro Suzuki and Koichi Ohshima and Koji Kato and Naoyuki Katayama and Motoko Yamaguchi",

note = "Funding Information: This study was supported by grants‐in‐aid from the Japan Agency for Medical Research and Development, AMED (JP15Ack0106157, JP16ck0106157, JP17ck0106157, JP18ck0106439), the Ministry of Labour, Health, and Welfare of Japan (201438142A), the director of Mie University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26‐A‐4, 29‐A‐3). Funding Information: We wish to thank Takuya Matsunaga (Hokuou Hospital), Noriko Usui (The Jikei University School of Medicine), and Akiko Kada (Nagoya Medical Center) as members of the Data and Safety Monitoring Board.",

year = "2023",

month = jun,

doi = "10.1111/cas.15784",

language = "English",

volume = "114",

pages = "2689--2691",

journal = "Cancer science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "6",

}

Miyazaki, K, Sakai, R, Iwaki, N, Yamamoto, G, Murayama, K, Nishikori, M, Sunami, K, Yoshida, I, Yano, H, Takahashi, N, Okamoto, A, Munemoto, S, Sawazaki, A, Suehiro, Y, Fukuhara, N, Wake, A, Arai, A, Masaki, Y, Toyama, K, Yokoyama, A, Tsunemine, H, Hasegawa, Y, Matsumoto, K, Yamada, T, Nishimura, Y, Tamaru, S, Asano, N, Miyawaki, K, Izutsu, K, Kinoshita, T, Suzuki, R, Ohshima, K, Kato, K, Katayama, N & Yamaguchi, M 2023, 'Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL', Cancer science, vol. 114, no. 6, pp. 2689-2691. https://doi.org/10.1111/cas.15784

TY - JOUR

T1 - Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

AU - Miyazaki, Kana

AU - Sakai, Rika

AU - Iwaki, Noriko

AU - Yamamoto, Go

AU - Murayama, Kayoko

AU - Nishikori, Momoko

AU - Sunami, Kazutaka

AU - Yoshida, Isao

AU - Yano, Hiroki

AU - Takahashi, Naoki

AU - Okamoto, Akinao

AU - Munemoto, Saori

AU - Sawazaki, Aiko

AU - Suehiro, Youko

AU - Fukuhara, Noriko

AU - Wake, Atsushi

AU - Arai, Ayako

AU - Masaki, Yasufumi

AU - Toyama, Kohtaro

AU - Yokoyama, Akihiro

AU - Tsunemine, Hiroko

AU - Hasegawa, Yuichi

AU - Matsumoto, Kenji

AU - Yamada, Tomomi

AU - Nishimura, Yuki

AU - Tamaru, Satoshi

AU - Asano, Naoko

AU - Miyawaki, Kohta

AU - Izutsu, Koji

AU - Kinoshita, Tomohiro

AU - Suzuki, Ritsuro

AU - Ohshima, Koichi

AU - Kato, Koji

AU - Katayama, Naoyuki

AU - Yamaguchi, Motoko

N1 - Funding Information: This study was supported by grants‐in‐aid from the Japan Agency for Medical Research and Development, AMED (JP15Ack0106157, JP16ck0106157, JP17ck0106157, JP18ck0106439), the Ministry of Labour, Health, and Welfare of Japan (201438142A), the director of Mie University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26‐A‐4, 29‐A‐3). Funding Information: We wish to thank Takuya Matsunaga (Hokuou Hospital), Noriko Usui (The Jikei University School of Medicine), and Akiko Kada (Nagoya Medical Center) as members of the Data and Safety Monitoring Board.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85150804785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150804785&partnerID=8YFLogxK

U2 - 10.1111/cas.15784

DO - 10.1111/cas.15784

M3 - Letter

C2 - 36929591

AN - SCOPUS:85150804785

SN - 1347-9032

VL - 114

SP - 2689

EP - 2691

JO - Cancer science

JF - Cancer science

IS - 6

ER -